Close this search box.

Clinical Trial: NRG GY005


Status: Closed

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

GY005 closed to accrual in US, Canada and South Korea effective October 2, 2020.